Author/Authors :
Turker، Kamuran نويسنده Department of Infectious Diseases, Ministry of Health Bagcilar State Hospital, Istanbul, Turkey Turker, Kamuran , Tas، Betul نويسنده Department of Dermatology, Ministry of Health Bagcilar State Hospital, Istanbul, Turkey Tas, Betul , Ozkaya، Murat نويسنده Department of Physical Medicine and Rehabilitation, Ministry of Health Bagcilar State Hospital, Istanbul, Turkey Ozkaya, Murat , Tas، Ebru نويسنده Department of Gastroenterology, Dumlupinari University Faculty of Medicine, Evliya Celebi Research and Training Hospital, Kutahya, Turkey Tas, Ebru , Caglar، Aysel نويسنده Department of Pathology, Ministry of Health Bagcilar State Hospital, Istanbul, Turkey Caglar, Aysel , Tetikkurt، Umit Seza نويسنده Department of Pathology, Ministry of Health Bagcilar State Hospital, Istanbul, Turkey Tetikkurt, Umit Seza
Abstract :
Various types of dermatological manifestations have been reported due to hepatitis C virus (HCV) infection and antiHCV therapy. Some of them have been described during IFN-based therapies. PEG-IFN-α-2a/RBV combination is used as the international standard of treatment for HCV infection for a long time. The combination therapy yields an adverse-event profile similar to standard interferon (IFN) therapy. Some of these adverse effects are rheumatologic, neuropsychiatric and dermatological manifestations including alopecia. We reported a 43-year-old woman with dystrophic anagen effluvium (DAE), rheumatoid arthritis and Hashimoto thyroiditis, which were developed under the combination therapy for chronic HCV infection. Although some cases of alopecia areata (AA) and telogen effluvium (TE) were reported in literature, no case of DAE associated with PEG-INF-α-2a /RBV combination therapy was reported previously.
